NCT05781711

Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Parkinson's disease (PD) is one of the most common neurodegenerative diseases characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) and aggregation of Lewy bodies in neurons. Although aging, oxidative damage and neuroinflammation have been recognized to play crucial roles in the pathogenesis of PD, the precise etiology remains obscure. Emerging evidence suggests PD is a systemic metabolic disease, and metabolic abnormality correlates with functional alternations in PD

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	levodopa-carbidopa	levodopa-carbidopa is the standard therapy used in Parkinson's disease
DRUG	Metformin	Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production

Timeline

• Start date: 2023-01-06
• Primary completion: 2025-01-20
• Completion: 2025-01-20
• First posted: 2023-03-23
• Last updated: 2026-03-13

Locations

1 site across 1 country: Egypt